It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
The company has been sold to Shinshin Pharmaceuticals
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Through the Sehat Sathi App business can access unsecured business loans at low interest
Subscribe To Our Newsletter & Stay Updated
